PH12017500934B1 - Sublingual formulation of riluzole - Google Patents
Sublingual formulation of riluzoleInfo
- Publication number
- PH12017500934B1 PH12017500934B1 PH1/2017/500934A PH12017500934A PH12017500934B1 PH 12017500934 B1 PH12017500934 B1 PH 12017500934B1 PH 12017500934 A PH12017500934 A PH 12017500934A PH 12017500934 B1 PH12017500934 B1 PH 12017500934B1
- Authority
- PH
- Philippines
- Prior art keywords
- riluzole
- sublingual formulation
- sublingual
- disclosed
- formulation
- Prior art date
Links
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 title abstract 4
- 229960004181 riluzole Drugs 0.000 title abstract 4
- 238000009472 formulation Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 206010031009 Oral pain Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462083094P | 2014-11-21 | 2014-11-21 | |
| PCT/US2015/061114 WO2016081472A1 (en) | 2014-11-21 | 2015-11-17 | Sublingual formulation of riluzole |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PH12017500934A1 PH12017500934A1 (en) | 2017-11-20 |
| PH12017500934B1 true PH12017500934B1 (en) | 2024-06-28 |
Family
ID=55085882
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH1/2017/500934A PH12017500934B1 (en) | 2014-11-21 | 2015-11-17 | Sublingual formulation of riluzole |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US11660267B2 (OSRAM) |
| EP (3) | EP3220891B1 (OSRAM) |
| JP (3) | JP6753860B2 (OSRAM) |
| KR (2) | KR102580378B1 (OSRAM) |
| CN (1) | CN107249567B (OSRAM) |
| AU (2) | AU2015350148B2 (OSRAM) |
| BR (1) | BR112017010423B1 (OSRAM) |
| CA (1) | CA2967662A1 (OSRAM) |
| CY (1) | CY1122469T1 (OSRAM) |
| DK (1) | DK3220891T3 (OSRAM) |
| EA (1) | EA038518B1 (OSRAM) |
| ES (2) | ES2882783T3 (OSRAM) |
| HR (1) | HRP20191892T8 (OSRAM) |
| HU (1) | HUE046869T2 (OSRAM) |
| IL (2) | IL278188B2 (OSRAM) |
| LT (1) | LT3220891T (OSRAM) |
| MX (1) | MX368838B (OSRAM) |
| PH (1) | PH12017500934B1 (OSRAM) |
| PL (1) | PL3220891T3 (OSRAM) |
| PT (1) | PT3220891T (OSRAM) |
| RS (1) | RS59490B1 (OSRAM) |
| SG (1) | SG11201703896QA (OSRAM) |
| SI (1) | SI3220891T1 (OSRAM) |
| WO (1) | WO2016081472A1 (OSRAM) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE061847T2 (hu) | 2016-10-11 | 2023-08-28 | Arvinas Operations Inc | Androgén receptor célzott degradálására alkalmas vegyületek és eljárások |
| RU2020130837A (ru) | 2018-02-21 | 2022-03-21 | ЭйАй ТЕРАПЬЮТИКС, ИНК. | Комбинационная терапия апилимодом и глутаматергическими агентами |
| MX2020012377A (es) * | 2018-05-27 | 2021-04-12 | Biohaven Therapeutics Ltd | Uso de tabletas de desintegracion orales de riluzol para el tratamiento de enfermedades. |
| US20210315865A1 (en) * | 2018-08-16 | 2021-10-14 | Biohaven Therapeutics Ltd. | Use of riluzole oral disintigrating tablets for treating diseases |
| IL292359A (en) * | 2019-10-22 | 2022-06-01 | Arvinas Operations Inc | Prostate cancer treatment methods |
| AU2021273458A1 (en) | 2020-05-09 | 2022-12-01 | Arvinas Operations, Inc. | Methods of manufacturing a bifunctional compound, ultrapure forms of the bifunctional compound, and dosage forms comprising the same |
| US20240016783A1 (en) * | 2020-10-05 | 2024-01-18 | Icahn School Of Medicine At Mount Sinai | Riluzole for the treatment of alzheimer's disease |
| WO2022103638A1 (en) | 2020-11-16 | 2022-05-19 | Orcosa Inc. | Cannabinoids in the treatment of autism spectrum disorder |
| US11672761B2 (en) | 2020-11-16 | 2023-06-13 | Orcosa Inc. | Rapidly infusing platform and compositions for therapeutic treatment in humans |
| CN113876735B (zh) * | 2021-10-20 | 2023-05-12 | 陇南市第一人民医院 | 一种利鲁唑微球制剂及其制备方法 |
| KR102625977B1 (ko) | 2021-11-24 | 2024-01-17 | 부산대학교 산학협력단 | 리루졸을 유효성분으로 포함하는 염증성 장질환 예방 또는 치료용 조성물 |
| WO2025122895A1 (en) | 2023-12-08 | 2025-06-12 | Arvinas Operations, Inc. | Use of androgen receptor degrader for the treatment of spinal and bulbar muscular atrophy |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2492258A1 (fr) * | 1980-10-17 | 1982-04-23 | Pharmindustrie | Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole |
| FR2702148B1 (fr) * | 1993-03-05 | 1995-04-07 | Rhone Poulenc Rorer Sa | Application d'anticonvulsivants dans le traitement du neuro-sida. |
| WO1995001782A2 (en) | 1993-07-09 | 1995-01-19 | R.P. Scherer Corporation | Method for making freeze dried drug dosage forms |
| US5457895A (en) | 1993-10-01 | 1995-10-17 | R. P. Scherer Corporation | Method of identifying freeze-dried dosage forms |
| US5837287A (en) | 1994-10-28 | 1998-11-17 | R P Scherer Corporation | Process for preparing solid pharmaceutical dosage forms |
| ATE260048T1 (de) * | 1996-12-20 | 2004-03-15 | Nutrinova Gmbh | Verfahren zur verstärkung der süsskraft und zur geschmacksverbesserung einer mischung hochintensiver süssstoffe |
| WO1998036738A1 (en) | 1997-02-20 | 1998-08-27 | Therics, Inc. | Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same |
| EP1001748B1 (en) | 1997-07-25 | 2006-04-19 | Alpex Pharma S.A. | A process for the preparation of a granulate suitable to the preparation of rapidly disintegrable mouth-soluble tablets |
| RU2233654C2 (ru) | 1998-11-20 | 2004-08-10 | Ртп Фарма Инк. | Диспергируемые стабилизированные фосфолипидом микрочастицы |
| JP2002531490A (ja) * | 1998-12-09 | 2002-09-24 | カイロン コーポレイション | 中枢神経系に薬剤を投与するための方法 |
| FR2787028B1 (fr) | 1998-12-15 | 2002-10-18 | Aventis Pharma Sa | Utilisation du riluzole dans le traitement des traumatismes acoustiques |
| US6284270B1 (en) | 1999-08-04 | 2001-09-04 | Drugtech Corporation | Means for creating a mass having structural integrity |
| US6316029B1 (en) | 2000-05-18 | 2001-11-13 | Flak Pharma International, Ltd. | Rapidly disintegrating solid oral dosage form |
| JP2001328947A (ja) * | 2000-05-19 | 2001-11-27 | Ritsuko Senba | 脳由来神経栄養因子発現促進剤 |
| US6432992B1 (en) * | 2000-06-05 | 2002-08-13 | Aventis Pharm Sa | Use of riluzole or its salts for the prevention and treatment of adrenoleukodystrophy |
| WO2003079972A2 (en) * | 2002-02-22 | 2003-10-02 | New River Parmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
| US6982251B2 (en) | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents |
| US6814978B2 (en) | 2000-12-29 | 2004-11-09 | Mcneil-Ppc, Inc. | Process for preparing a soft tablet |
| US6509040B1 (en) | 2001-06-22 | 2003-01-21 | R.P. Scherer Corporation | Fast dispersing dosage forms essentially free of mammalian gelatin |
| AU2002334939A1 (en) | 2001-10-12 | 2003-04-22 | Eugene R. Cooper | Compositions having a combination of particles for immediate release and for controlled release |
| EP1485296B1 (en) | 2002-02-13 | 2011-07-20 | Michael K. Weibel | Drug dose - form and method of manufacture |
| WO2004105756A2 (en) * | 2003-05-29 | 2004-12-09 | Novartis Ag | Combination comprising (a) a neuroprotecting agent and (b) an agent binding to gadph and pharmaceutical use thereof |
| US7282217B1 (en) | 2003-08-29 | 2007-10-16 | Kv Pharmaceutical Company | Rapidly disintegrable tablets |
| WO2005084377A2 (en) * | 2004-03-03 | 2005-09-15 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and riluzole |
| US8158152B2 (en) | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
| US8048449B2 (en) | 2005-12-27 | 2011-11-01 | Jubilant Organosys Ltd. | Mouth dissolving pharmaceutical composition and process for preparing the same |
| GB0625322D0 (en) * | 2006-12-19 | 2007-01-24 | Pharmakodex Ltd | Pharmaceutical compositions |
| EP1980240A1 (en) | 2007-04-11 | 2008-10-15 | Cephalon France | Lyophilized pharmaceutical compositions and methods of making and using same |
| WO2009002084A2 (en) | 2007-06-27 | 2008-12-31 | Hanmi Pharm. Co., Ltd. | Method for preparing rapidly disintegrating formulation for oral administration and apparatus for preparing and packing the same |
| WO2010009279A1 (en) * | 2008-07-15 | 2010-01-21 | University Of Medicine And Dentistry Of New Jersey | Methods and compositions for treating alzheimer's disease |
| US8256233B2 (en) | 2008-10-31 | 2012-09-04 | The Invention Science Fund I, Llc | Systems, devices, and methods for making or administering frozen particles |
| US8221480B2 (en) | 2008-10-31 | 2012-07-17 | The Invention Science Fund I, Llc | Compositions and methods for biological remodeling with frozen particle compositions |
| WO2010096869A1 (en) * | 2009-02-26 | 2010-09-02 | Steven Michael Weiss | An agent for improving inotropy and lusitropy, and for treating diseases causing or caused by poor contractility or relaxation of the heart |
| EP2228054A1 (en) | 2009-03-13 | 2010-09-15 | ITALFARMACO S.p.A. | Riluzole aqueous suspensions |
| US8313768B2 (en) | 2009-09-24 | 2012-11-20 | Mcneil-Ppc, Inc. | Manufacture of tablet having immediate release region and sustained release region |
| HUE038653T2 (hu) * | 2011-03-01 | 2018-11-28 | Pharnext | Neurológiai rendellenességek baclofen és acamprosate alapú terápiája |
| US9241933B2 (en) | 2011-03-01 | 2016-01-26 | Pharnext | Compositions for treating amyotrophic lateral sclerosis |
| UA113165C2 (xx) | 2011-03-01 | 2016-12-26 | Застосування комбінації баклофену і акампросату для лікування неврологічних захворювань та композиція, яка містить баклофен і акампросат | |
| KR101951220B1 (ko) * | 2011-07-13 | 2019-02-22 | 싸이토키네틱스, 인코포레이티드 | 조합 als 치료법 |
| CA3075331A1 (en) | 2012-03-01 | 2013-09-06 | Pharnext | New compositions for treating amyotrophic lateral sclerosis |
| AU2015350142A1 (en) | 2014-11-21 | 2017-06-15 | Biohaven Pharmaceutical Holding Company Ltd. | Sublingual administration of riluzole |
| CA2978158C (en) * | 2015-03-03 | 2022-04-12 | Biohaven Pharmaceutical Holding Company Ltd. | Riluzole prodrugs and their use |
-
2015
- 2015-11-17 KR KR1020177016906A patent/KR102580378B1/ko active Active
- 2015-11-17 CA CA2967662A patent/CA2967662A1/en active Pending
- 2015-11-17 IL IL278188A patent/IL278188B2/en unknown
- 2015-11-17 DK DK15823415T patent/DK3220891T3/da active
- 2015-11-17 SG SG11201703896QA patent/SG11201703896QA/en unknown
- 2015-11-17 KR KR1020237031525A patent/KR102811263B1/ko active Active
- 2015-11-17 BR BR112017010423-7A patent/BR112017010423B1/pt active IP Right Grant
- 2015-11-17 HU HUE15823415A patent/HUE046869T2/hu unknown
- 2015-11-17 PH PH1/2017/500934A patent/PH12017500934B1/en unknown
- 2015-11-17 ES ES19186196T patent/ES2882783T3/es active Active
- 2015-11-17 EA EA201790958A patent/EA038518B1/ru unknown
- 2015-11-17 WO PCT/US2015/061114 patent/WO2016081472A1/en not_active Ceased
- 2015-11-17 LT LT15823415T patent/LT3220891T/lt unknown
- 2015-11-17 RS RS20191376A patent/RS59490B1/sr unknown
- 2015-11-17 US US15/100,160 patent/US11660267B2/en active Active
- 2015-11-17 EP EP15823415.3A patent/EP3220891B1/en active Active
- 2015-11-17 CN CN201580073630.4A patent/CN107249567B/zh active Active
- 2015-11-17 PL PL15823415T patent/PL3220891T3/pl unknown
- 2015-11-17 EP EP19186196.2A patent/EP3616686B8/en active Active
- 2015-11-17 SI SI201530956T patent/SI3220891T1/sl unknown
- 2015-11-17 HR HRP20191892TT patent/HRP20191892T8/hr unknown
- 2015-11-17 ES ES15823415T patent/ES2751300T3/es active Active
- 2015-11-17 PT PT158234153T patent/PT3220891T/pt unknown
- 2015-11-17 AU AU2015350148A patent/AU2015350148B2/en active Active
- 2015-11-17 MX MX2017006446A patent/MX368838B/es active IP Right Grant
- 2015-11-17 JP JP2017545858A patent/JP6753860B2/ja active Active
- 2015-11-17 EP EP21169884.0A patent/EP4039247B1/en active Active
-
2017
- 2017-05-15 IL IL252285A patent/IL252285B/en active IP Right Grant
-
2019
- 2019-10-22 CY CY20191101095T patent/CY1122469T1/el unknown
-
2020
- 2020-08-20 JP JP2020139429A patent/JP2021001173A/ja active Pending
- 2020-10-25 US US17/079,498 patent/US12121609B2/en active Active
-
2021
- 2021-02-17 AU AU2021201034A patent/AU2021201034B2/en active Active
-
2023
- 2023-02-03 JP JP2023015640A patent/JP2023065398A/ja active Pending
-
2024
- 2024-10-21 US US18/921,046 patent/US20250114301A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12017500933A1 (en) | Sublingual administration of riluzole | |
| PH12017500934B1 (en) | Sublingual formulation of riluzole | |
| MX2018004947A (es) | Metodos para el tratamiento de sindrome de angelman y de los trastornos relacionados. | |
| MX2017014191A (es) | Metodos de tratamiento de una enfermedad neurodegenerativa. | |
| TW201713333A (en) | Methods of treating a neurodegenerative disease | |
| PH12016502530A1 (en) | Pharmaceutical compositions comprising dgla and use of same | |
| NZ722600A (en) | Methods of treating mild brain injury | |
| SG10201804034QA (en) | Methods for treating hypotension | |
| GEP20196984B (en) | Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder | |
| PH12016502233A1 (en) | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine | |
| NZ730092A (en) | Use of cysteamine in treating infections caused by yeasts/moulds | |
| EA201692020A1 (ru) | Пролекарственные средства янтарной кислоты для применения в лечении лактоацидоза или индуцируемого лекарственными средствами побочного действия вследствие связанных с комплексом i нарушений окислительного фосфорилирования в митохондриях | |
| MX382608B (es) | Tratamiento del prurito urémico. | |
| PH12016502236A1 (en) | (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine | |
| MY198753A (en) | Treatment of androgen deprivation therapy associated symptoms | |
| MX2016011706A (es) | Formulaciones de progesterona. | |
| MX2023003924A (es) | Metodos de administracion de tratamiento antifibrotico. | |
| RU2014154366A (ru) | Применение пробиотического штамма микроорганизма enterococcus faecium l3 для лечения нейродегенеративных заболеваний | |
| NZ747201A (en) | (+)-azasetron for use in the treatment of ear disorders | |
| MA40574A (fr) | Traitement de maladies fibrotiques | |
| MX2016010919A (es) | 4-bencilsulfonil-2-butenonitrilo. | |
| UA104614U (uk) | Спосіб лікування хронічного токсокарозу в поєднанні з ентеробіозом у дорослих | |
| PH12014000104A1 (en) | Therapeutic methods and compositions for treating diabetes | |
| UA91619U (uk) | Спосіб підтримуючого лікування при генералізованому пародонтиті | |
| IN2014DE00822A (OSRAM) |